RT Journal Article
SR Electronic
T1 Genomic Epidemiology of SARS-CoV-2 in Seychelles, 2020-2021
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.03.18.22272503
DO 10.1101/2022.03.18.22272503
A1 Morobe, John M.
A1 Didon, Dwayne
A1 Pool, Brigitte
A1 Lambisia, Arnold W.
A1 Makori, Timothy
A1 Mohammed, Khadija Said
A1 de Laurent, Zaydah R.
A1 Ndwiga, Leonard
A1 Mburu, Maureen W.
A1 Moraa, Edidah
A1 Murunga, Nickson
A1 Musyoki, Jennifer
A1 Mwacharo, Jedida
A1 Nyamako, Lydia
A1 Riako, Debra
A1 Ephnatus, Pariken
A1 Gambo, Faith
A1 Naimani, Josephine
A1 Namulondo, Joyce
A1 Dratibi, Fred Athanasius
A1 Ahmed, Yahaya Ali
A1 Gumede, Nicksy
A1 Achilla, Rachel A.
A1 Borus, Peter K.
A1 Wanjohi, Dorcas
A1 Tessema, Sofonias K.
A1 Mwangangi, Joseph
A1 Bejon, Philip
A1 Nokes, D. James
A1 Ochola-Oyier, Lynette Isabella
A1 Githinji, George
A1 Biscornet, Leon
A1 Agoti, Charles N.
YR 2022
UL http://medrxiv.org/content/early/2022/03/21/2022.03.18.22272503.abstract
AB By 31st December 2021, Seychelles, an archipelago of 115 islands in the Indian Ocean, had confirmed 24,788 cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The first SARS-CoV-2 cases in Seychelles were reported on 14th March 2020, but cases remained low until January 2021, when a surge of SARS-CoV-2 cases was observed on the islands. Here, we investigated the potential drivers of the surge by genomic analysis 1,056 SARS-CoV-2 positive samples collected in Seychelles between 14th March 2020 and 31st December 2021. The Seychelles genomes were classified into 32 Pango lineages, 1,042 of which fell within four variants of concern i.e., Alpha, Beta, Delta and Omicron. Sporadic of SARS-CoV-2 detected in Seychelles in 2020 were mainly of lineage B.1 (Europe origin) but this lineage was rapidly replaced by Beta variant starting January 2021, and which was also subsequently replaced by the Delta variant in May 2021 that dominated till November 2021 when Omicron cases were identified. Using ancestral state reconstruction approach, we estimated at least 78 independent SARS-CoV-2 introduction events into Seychelles during the study period. Majority of viral introductions into Seychelles occurred in 2021, despite substantial COVID-19 restrictions in place during this period. We conclude that the surge of SARS-CoV-2 cases in Seychelles in January 2021 was primarily due to introduction of the more transmissible SARS-CoV-2 variants into the islands.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis works was supported by the National Institute for Health Research (NIHR) (project references 17/63/82 and 16/136/33) using UK aid from the UK Government to support global health research, The UK Foreign, Commonwealth and Development Office and Wellcome Trust (grant# 220985/Z/20/Z) The views expressed in this publication are those of the author (s) and not necessarily those of NIHR or the Department of Health and Social Care, Foreign Commonwealth and Development Office. This work was also supported by the Seychelles Public Health Laboratory (Public Health Authority), Africa-CDC, WHO-Afro, WHO-Seychelles, ASLM, and WHO-Kenya offices.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The whole genome sequencing study protocol was reviewed and approved by the Scientific and Ethics Review Committee (SERU) at KEMRI, (SERU #4035). Individual patient consent requirement was waivered by the committee as the sequenced samples were part of the public health emergency response.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data generated and analysis script for this manuscript will be available from the Virus Epidemiology and Control, Kenya Medical Research Institute (KEMRI) Wellcome Trust Research Programme data server, https://doi.org/10.7910/DVN/AYT2UA. https://doi.org/10.7910/DVN/AYT2UA